PD-L1 regulation revisited: impact on immunotherapeutic strategies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD-L1 regulation revisited: impact on immunotherapeutic strategies

Published:2021-09 Issue:9 Volume:27 Page:868-881
ISSN:1471-4914
Container-title:Trends in Molecular Medicine
language:en
Short-container-title:Trends in Molecular Medicine

Author:

Lucibello Giulia^ORCID,Mograbi Baharia^ORCID,Milano Gerard^ORCID,Hofman Paul^ORCID,Brest Patrick^ORCID

Funder

Bristol-Myers Squibb Foundation

Agence nationale de la recherche

INSERM

Fondation ARC pour la Recherche sur Le Cancer

INCa

Canceropôle PACA

Publisher

Elsevier BV

Subject

Molecular Biology,Molecular Medicine

Reference102 articles.

1. Cancer immunologists scoop medicine Nobel prize;Ledford;Nature,2018

2. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells;André;Cell,2018

3. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4;Qin;Mol. Cancer,2019

4. Immune escape: a critical hallmark in solid tumors;Mortezaee;Life Sci.,2020

5. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment;Zhao;Cell. Mol. Immunol.,2020

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zosuquidar Promotes Antitumor Immunity by Inducing Autophagic Degradation of PD‐L1;Advanced Science;2024-09-04

2. Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges;Acta Pharmaceutica Sinica B;2024-09

3. EBV + B cell-derived exosomes promote EBV-associated T/NK-cell lymphoproliferative disease immune evasion by STAT3/IL-10/PD-L1 pathway;Immunologic Research;2024-08-20

4. PD-L1 at the crossroad between RNA metabolism and immunosuppression;Trends in Molecular Medicine;2024-07

5. The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment;Cancer Letters;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3